GO TO: Recent Comment Letters
ALL |
All 10-K/Qs
Large
Mid
Small
Micro
|
Earnings Release
Proxy
|
SORT BY :
Most Recent
Company Name
| Company | Time | Size | View | Financials | Document | SEC | Period | Revenue MRQ | Assets | EPS Diluted | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Vivos Therapeutics, Inc. (VVOS) | 8/15/2026 4:04:01 AM | Micro | View | Financials | 10-Q | SEC | 2Q 2026 ending: 6/30/2026 | Rev: $5,153,000 +34.9% | Assets $24,144,000 | EPS -$0.31 | |
| Vivos Therapeutics, Inc. (VVOS) | 8/14/2026 4:33:44 PM | View | Financials | Earnings | WIRE | 2Q 2026 | Rev $5,153,000 +34.9% | Assets $24,144,000 | EPS -$0.31 | Export Earnings Model | |
| Vivos Therapeutics, Inc. (VVOS) | 5/20/2026 5:11:31 PM | Micro | View | Financials | 10-Q | SEC | 1Q 2026 ending: 3/31/2026 | Rev: $5,141,000 +70.5% | Assets $25,043,000 | EPS -$0.52 | |
| Vivos Therapeutics, Inc. (VVOS) | 5/20/2026 4:11:37 PM | View | Financials | Earnings | WIRE | 1Q 2026 | Rev $5,141,000 +70.5% | Assets $25,043,000 | EPS -$0.52 | Export Earnings Model | |
| Vivos Therapeutics, Inc. (VVOS) | 4/15/2026 5:16:22 PM | View | Financials | Earnings | SEC | 1Q 2026 | Rev $5,141,000 +70.5% | Assets $25,043,000 | EPS -$0.52 | Export Earnings Model | |
| Vivos Therapeutics, Inc. (VVOS) | 4/15/2026 5:15:35 PM | Micro | View | Financials | 10-K | SEC | Y 2025 ending: 12/31/2025 | Rev: $17,443,000 +16.0% | Assets $25,152,000 | EPS -$2.07 | |
| Vivos Therapeutics, Inc. (VVOS) | 11/19/2025 4:46:21 PM | View | Financials | Earnings | SEC | 3Q 2025 | Rev $6,783,000 +75.7% | Assets $25,644,000 | EPS -$0.49 | Export Earnings Model | |
| Vivos Therapeutics, Inc. (VVOS) | 11/19/2025 4:15:36 PM | Micro | View | Financials | 10-Q | SEC | 3Q 2025 ending: 9/30/2025 | Rev: $6,783,000 +75.7% | Assets $25,644,000 | EPS -$0.49 | |
| Vivos Therapeutics, Inc. (VVOS) | 9/29/2025 6:03:00 AM | View | Proxy | SEC | Y 2024 | ||||||
| Vivos Therapeutics, Inc. (VVOS) | 8/20/2025 4:06:03 PM | View | Financials | Earnings | SEC | 2Q 2025 | Rev $3,820,000 -5.8% | Assets $26,033,000 | EPS -$0.55 | Export Earnings Model | |
| Vivos Therapeutics, Inc. (VVOS) | 8/19/2025 4:16:45 PM | Micro | View | Financials | 10-Q | SEC | 2Q 2025 ending: 6/30/2025 | Rev: $3,820,000 -5.8% | Assets $26,033,000 | EPS -$0.55 | |
| Vivos Therapeutics, Inc. (VVOS) | 5/15/2025 5:25:49 PM | View | Financials | Earnings | SEC | 1Q 2025 | Rev $3,016,000 -11.8% | Assets $11,282,000 | EPS -$0.45 | Export Earnings Model | |
| Vivos Therapeutics, Inc. (VVOS) | 5/15/2025 4:13:38 PM | Micro | View | Financials | 10-Q | SEC | 1Q 2025 ending: 3/31/2025 | Rev: $3,016,000 -11.8% | Assets $11,282,000 | EPS -$0.45 | |
| Vivos Therapeutics, Inc. (VVOS) | 3/31/2025 5:32:11 PM | View | Financials | Earnings | SEC | Y 2024 | Rev $3,698,000 +13.9% | Assets $15,284,000 | EPS -$0.28 | Export Earnings Model | |
| Vivos Therapeutics, Inc. (VVOS) | 3/31/2025 4:32:46 PM | Micro | View | Financials | 10-K | SEC | Y 2024 ending: 12/31/2024 | Rev: $15,031,000 +8.9% | Assets $15,284,000 | EPS -$2.22 | |
| Vivos Therapeutics, Inc. (VVOS) | 11/14/2024 4:30:32 PM | Micro | View | Financials | 10-Q | SEC | 3Q 2024 ending: 9/30/2024 | Rev: $3,860,000 +16.9% | Assets $15,347,000 | EPS -$0.40 | |
| Vivos Therapeutics, Inc. (VVOS) | 11/14/2024 4:21:07 PM | View | Financials | Earnings | SEC | 3Q 2024 | Rev $3,860,000 +16.9% | Assets $15,347,000 | EPS -$0.40 | Export Earnings Model | |
| Vivos Therapeutics, Inc. (VVOS) | 10/7/2024 5:04:17 PM | View | Proxy | SEC | Y 2023 | ||||||
| Vivos Therapeutics, Inc. (VVOS) | 8/15/2024 6:06:15 AM | View | Financials | Earnings | SEC | 2Q 2024 | Rev $4,054,000 +19.4% | Assets $15,842,000 | EPS -$0.60 | Export Earnings Model | |
| Vivos Therapeutics, Inc. (VVOS) | 8/14/2024 4:35:49 PM | Micro | View | Financials | 10-Q | SEC | 2Q 2024 ending: 6/30/2024 | Rev: $4,054,000 +19.4% | Assets $15,842,000 | EPS -$0.60 | |
| Vivos Therapeutics, Inc. (VVOS) | 7/30/2024 6:16:07 AM | Micro | View | Financials | 10-K/A | SEC | Y 2023 ending: 12/31/2023 | Rev: $13,801,000 -13.9% | Assets $10,730,000 | EPS -$11.14 | |
| Vivos Therapeutics, Inc. (VVOS) | 5/15/2024 2:55:54 PM | View | Financials | Earnings | SEC | 1Q 2024 | Rev $3,419,000 -11.4% | Assets $11,804,000 | EPS -$1.63 | Export Earnings Model | |
| Vivos Therapeutics, Inc. (VVOS) | 5/14/2024 4:28:18 PM | Micro | View | Financials | 10-Q | SEC | 1Q 2024 ending: 3/31/2024 | Rev: $3,419,000 -11.4% | Assets $11,804,000 | EPS -$1.63 | |
| Vivos Therapeutics, Inc. (VVOS) | 3/29/2024 6:13:17 AM | View | Financials | Earnings | SEC | Y 2023 | Rev $3,248,000 -17.8% | Assets $10,730,000 | EPS -$3.05 | Export Earnings Model | |
| Vivos Therapeutics, Inc. (VVOS) | 3/28/2024 4:48:48 PM | Micro | View | Financials | 10-K | SEC | Y 2023 ending: 12/31/2023 | Rev: $13,801,000 -13.9% | Assets $10,730,000 | EPS -$11.14 | |
| Vivos Therapeutics, Inc. (VVOS) | 11/15/2023 4:03:28 AM | Micro | View | Financials | 10-Q | SEC | 3Q 2023 ending: 9/30/2023 | Rev: $3,301,000 -22.3% | Assets $10,317,000 | EPS -$1.75 | |
| Vivos Therapeutics, Inc. (VVOS) | 11/14/2023 4:06:47 PM | View | Financials | Earnings | WIRE | 3Q 2023 | Rev $3,301,000 -22.3% | Assets $10,317,000 | EPS -$1.75 | Export Earnings Model | |
| Vivos Therapeutics, Inc. (VVOS) | 8/28/2023 9:02:24 AM | View | Proxy | SEC | Y 2022 | ||||||
| Vivos Therapeutics, Inc. (VVOS) | 8/16/2023 4:32:27 PM | View | Financials | Earnings | SEC | 2Q 2023 | Rev $3,395,000 -18.9% | Assets $13,749,000 | EPS -$4.62 | Export Earnings Model | |
| Vivos Therapeutics, Inc. (VVOS) | 8/16/2023 4:26:29 PM | Micro | View | Financials | 10-Q | SEC | 2Q 2023 ending: 6/30/2023 | Rev: $3,395,000 -18.9% | Assets $13,749,000 | EPS -$4.62 | |
| Vivos Therapeutics, Inc. (VVOS) | 6/8/2023 5:01:21 PM | View | Financials | Earnings | SEC | 1Q 2023 | Rev $3,857,000 +5.8% | Assets $17,100,000 | EPS -$1.72 | Export Earnings Model | |
| Vivos Therapeutics, Inc. (VVOS) | 6/8/2023 4:26:42 PM | Micro | View | Financials | 10-Q | SEC | 1Q 2023 ending: 3/31/2023 | Rev: $3,857,000 +5.8% | Assets $17,100,000 | EPS -$1.72 | |
| Vivos Therapeutics, Inc. (VVOS) | 3/30/2023 5:15:49 PM | View | Financials | Earnings | SEC | Y 2022 | Rev $3,950,000 -10.1% | Assets $13,720,000 | EPS -$5.00 | Export Earnings Model | |
| Vivos Therapeutics, Inc. (VVOS) | 3/30/2023 4:31:41 PM | Micro | View | Financials | 10-K | SEC | Y 2022 ending: 12/31/2022 | Rev: $16,024,000 -5.1% | Assets $13,720,000 | EPS -$25.90 | |
| Vivos Therapeutics, Inc. (VVOS) | 12/20/2022 4:26:16 PM | Micro | View | Financials | 10-Q | SEC | 3Q 2022 ending: 9/30/2022 | Rev: $4,246,000 -6.6% | Assets $18,400,000 | EPS -$6.40 | |
| Vivos Therapeutics, Inc. (VVOS) | 12/20/2022 4:16:51 PM | View | Financials | Earnings | SEC | 3Q 2022 | Rev $4,246,000 -6.6% | Assets $18,400,000 | EPS -$6.40 | Export Earnings Model | |
| Vivos Therapeutics, Inc. (VVOS) | 12/20/2022 4:16:13 PM | Micro | View | Financials | 10-Q | SEC | 2Q 2022 ending: 6/30/2022 | Rev: $4,184,000 -7.0% | Assets $24,375,000 | EPS -$0.33 | |
| Vivos Therapeutics, Inc. (VVOS) | 11/25/2022 8:14:26 AM | Micro | View | Financials | 10-Q/A | SEC | 1Q 2022 ending: 3/31/2022 | Rev: $3,644,000 +5.7% | Assets $29,556,000 | EPS -$0.25 | |
| Vivos Therapeutics, Inc. (VVOS) | 7/14/2022 12:24:42 PM | View | Proxy | SEC | Y 2021 | ||||||
| Vivos Therapeutics, Inc. (VVOS) | 5/16/2022 5:21:44 PM | Micro | View | Financials | 10-Q | SEC | 1Q 2022 ending: 3/31/2022 | Rev: $3,644,000 +5.7% | Assets $29,556,000 | EPS -$0.25 | |
| Vivos Therapeutics, Inc. (VVOS) | 5/16/2022 4:18:22 PM | View | Financials | Earnings | SEC | 1Q 2022 | Rev $3,644,000 +5.7% | Assets $29,556,000 | EPS -$0.25 | Export Earnings Model | |
| Vivos Therapeutics, Inc. (VVOS) | 3/31/2022 5:20:18 PM | View | Financials | Earnings | SEC | Y 2021 | Rev $4,394,000 +32.9% | Assets $33,689,000 | EPS -$23.88 | Export Earnings Model | |
| Vivos Therapeutics, Inc. (VVOS) | 3/31/2022 4:26:19 PM | Micro | View | Financials | 10-K | SEC | Y 2021 ending: 12/31/2021 | Rev: $16,885,000 +29.2% | Assets $33,689,000 | EPS -$23.88 | |
| Vivos Therapeutics, Inc. (VVOS) | 11/15/2021 4:35:38 PM | Micro | View | Financials | 10-Q | SEC | 3Q 2021 ending: 9/30/2021 | Rev: $4,546,000 +38.1% | Assets $41,024,206 | ||
| Vivos Therapeutics, Inc. (VVOS) | 11/15/2021 4:26:27 PM | View | Financials | Earnings | SEC | 3Q 2021 | Rev $4,546,000 +38.1% | Assets $41,024,206 | Export Earnings Model | ||
| Vivos Therapeutics, Inc. (VVOS) | 8/12/2021 4:34:32 PM | Micro | View | Financials | 10-Q | SEC | 2Q 2021 ending: 6/30/2021 | Rev: $4,497,000 +37.5% | Assets $46,156,308 | ||
| Vivos Therapeutics, Inc. (VVOS) | 8/12/2021 4:18:33 PM | View | Financials | Earnings | SEC | 2Q 2021 | Rev $4,497,000 +37.5% | Assets $46,156,308 | Export Earnings Model | ||
| Vivos Therapeutics, Inc. (VVOS) | 6/29/2021 4:39:41 PM | View | Proxy | SEC | Y 2020 | ||||||
| Vivos Therapeutics, Inc. (VVOS) | 5/17/2021 10:37:59 PM | Micro | View | Financials | 10-Q | SEC | 1Q 2021 ending: 3/31/2021 | Rev: $3,448,000 +7.9% | Assets $21,953,902 | ||
| Vivos Therapeutics, Inc. (VVOS) | 5/17/2021 4:22:36 PM | View | Earnings | SEC | 1Q 2021 | Rev $3,448,000 +7.9% | Assets $21,953,902 | ||||
| Vivos Therapeutics, Inc. (VVOS) | 3/25/2021 7:01:44 PM | Micro | View | Financials | 10-K | SEC | Y 2020 ending: 12/31/2020 | Rev: $13,066,000 +14.7% | Assets $25,327,000 | EPS -$1.40 | |
| Vivos Therapeutics, Inc. (VVOS) | 3/25/2021 6:56:07 PM | View | Earnings | SEC | Y 2020 | Rev $3,306,703 | Assets $25,327,000 | EPS -$0.88 |